================================================================================


                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                   -----------
                                    FORM 8-A
                                   -----------

                FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
                       PURSUANT TO SECTION 12(b) OR 12(g)
                     OF THE SECURITIES EXCHANGE ACT OF 1934


                          BIO-TECHNOLOGY GENERAL CORP.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)


          DELAWARE                                        13-3033811
   -----------------------                            ----------------------
   (State of incorporation                            (I.R.S. Employer
    or organization)                                    Identification No.)


        70 WOOD AVENUE SOUTH
        ISELIN, NEW JERSEY                                  08830
  ----------------------------------------                ----------
  (Address of principal executive offices)                (Zip Code)


        Securities to be registered pursuant to Section 12(b) of the Act:


      Title of each class                Name of each exchange on which
      to be so registered                each class is to be registered
      -------------------                ------------------------------
            NONE                                      NONE


     If this form relates to the registration of a class of securities pursuant
to Section 12(b) of the Exchange Act and is effective pursuant to General
Instruction A.(c), check the following box. [ ]

     If this form relates to the registration of a class of securities pursuant
to Section 12(g) of the Exchange Act and is effective pursuant to General
Instruction A.(d), check the following box. [x]

     Securities Act registration statement file number to which this form
relates: _____________ (if applicable)

     Securities to be registered pursuant to Section 12(g) of the Act:


                         PREFERRED STOCK PURCHASE RIGHTS
                         -------------------------------
                                (Title of Class)

================================================================================





                 INFORMATION REQUIRED IN REGISTRATION STATEMENT

Item 1. Description of Registrant's Securities to be Registered.

     On October 7, 1998, the Board of Directors of Bio-Technology General Corp.
(the "Company") adopted a Shareholder Rights Plan (the "Rights Plan"). The
purpose of the Rights Plan is to deter certain coercive takeover tactics and
enable the Board of Directors to represent effectively the interests of
stockholders in the event of a takeover attempt. The Rights Plan does not deter
negotiated mergers or business combinations that the Board of Directors
determines to be in the best interests of the Company and its stockholders.

     To implement the Rights Plan the Board of Directors declared a dividend of
one preferred share purchase right (a "Right") for each outstanding share of
common stock, par value $.01 per share (the "Common Shares"), of the Company.
The dividend is payable on October 22, 1998 (the "Record Date") to the
stockholders of record at the close of business on that date. Each Right
entitles the registered holder to purchase from the Company one one-thousandth
of a share of Series A Junior Participating Cumulative Preferred Stock, par
value $.01 per share (the "Preferred Shares"), of the Company at a price of
$45.00 per one one-thousandth of a Preferred Share (the "Purchase Price"),
subject to adjustment. The description and terms of the Rights are set forth in
a Rights Agreement (the "Rights Agreement") between the Company and American
Stock Transfer & Trust Company, as Rights Agent (the "Rights Agent").

RIGHTS ATTACH TO COMMON SHARES INITIALLY

     Initially and until a Distribution Date (as defined below) occurs, the
Rights are attached to all Common Shares and no separate Rights certificates
will be issued. During this initial period,

     o    the Rights are not exercisable;

     o    the Rights are transferred with the Common Shares and are not
          transferable separately from the Common Shares;

     o    new Common Share certificates issued will contain a notation
          incorporating the Rights Agreement by reference; and

     o    the transfer of any Common Shares will also constitute the transfer of
          the Rights associated with those Common Shares.

DISTRIBUTION OF RIGHTS

     Separate certificates evidencing the Rights will be mailed to holders of
record of the Common Shares on the "Distribution Date." The Distribution Date is
the earlier to occur of the following two events:

                                      -2-




     o    the tenth day after a public announcement that a person or group of
          affiliated or associated persons has acquired 20% or more of the
          outstanding Common Shares (thereby becoming an "Acquiring Person"
          under the Rights Plan); or

     o    the tenth business day (or such later date as may be determined by
          action of the Board of Directors prior to such time as any person or
          group of affiliated or associated persons becomes an Acquiring Person)
          after the commencement or announcement of a tender or exchange offer
          by a person or group for 20% or more of the outstanding Common Shares.

     Acquisitions by the Company, any subsidiary or employee benefit plan of the
Company or any other person approved in advance by the Board of Directors will
not result in such person becoming an Acquiring Person.

     After the Distribution Date, the Rights will be tradable separately from
the Common Shares. After the Distribution Date and after the Company's right to
redeem (as described below) has expired, the Rights will be exercisable in two
different ways depending on the circumstances as set forth below.

RIGHT TO PURCHASE COMPANY STOCK

     If a person or group acquires 20% or more of the outstanding Common Shares
(thereby becoming an Acquiring Person) and the Company's redemption right has
expired, each holder of a Right (except those held by the Acquiring Person and
its affiliates and associates) will have the right to purchase, upon exercise,
Common Shares (or, in certain circumstances, Preferred Shares or other similar
securities of the Company) having a value equal to two times the exercise price
of the Right. In other words, the Rights holders other than the Acquiring Person
may purchase Common Shares at a 50% discount.

     For example, at the exercise price of $45 per Right, each Right not owned
by an Acquiring Person would entitle its holder to purchase $90 worth of Common
Shares (or other consideration, as noted above) for $45. Assuming a value of $9
per Common Share at such time, the holder of each valid Right would be entitled
to purchase ten Common Shares for $45.

RIGHT TO PURCHASE ACQUIRING PERSON STOCK

     Alternatively, if, in a transaction not approved by the Board of Directors,
the Company is acquired in a merger or other business combination or 50% or more
of its assets or earning power are sold after a person or group has become an
Acquiring Person, and the Company's redemption right has expired, proper
provision will be made so that each holder of a Right will thereafter have the
right to purchase, upon exercise, that number of shares of common stock of the
acquiring company as have a market value of two times the exercise price of the
Right. In other words, a Rights holder may purchase the acquiring company's
common stock at a 50% discount

                                      -3-




EXCHANGE OF COMPANY STOCK FOR RIGHTS

     At any time after any person or group becomes an Acquiring Person and
before the Acquiring Person acquires 50% or more of the outstanding Common
Shares, the Board of Directors may exchange the Rights (other than Rights owned
by the Acquiring Person which will have become void), in whole or in part, at an
exchange ratio of one Common Share, or one one-thousandth of a Preferred Share
(or of a share of a class or series of the Company's preferred stock having
equivalent rights, preferences and privileges), per Right (subject to
adjustment).

REDEMPTION

     The Rights are redeemable by the Company in whole but not in part at a
price of $.01 per Right at any time up to and including the tenth day after the
time that a person or a group has become an Acquiring Person, subject to
extension of this redemption period by the Board of Directors. Immediately upon
redemption the right to exercise will terminate and the only right of holders
will be to receive the redemption price.

EXPIRATION OF RIGHTS

     The Rights will expire on October 6, 2008 unless the expiration date is
extended by amendment as described below or unless the Rights are earlier
redeemed or exchanged by the Company as described above.

AMENDMENTS

     As long as the Rights are redeemable, the terms of the Rights may be
amended by the Board of Directors in its discretion without the consent of the
Rights holders. After that time, no amendment may adversely affect the interests
of the Rights holders (other than the Acquiring Person).

MISCELLANEOUS

     The number of outstanding Rights and the number of one
one-thousandths of a Preferred Share issuable upon exercise of each Right are
subject to adjustment under certain circumstances.

     Because of the nature of the Preferred Shares' dividend, liquidation and
voting rights, the value of the one one-thousandth interest in a Preferred Share
that may be purchased upon exercise of each Right should approximate the value
of one Common Share.

     Until a Right is exercised, a Rights holder, as such, will have no rights
as a stockholder of the Company, including, without limitation, the right to
vote or to receive dividends.

                                      -4-




     A copy of the Rights Agreement has been filed with the Securities and
Exchange Commission as an Exhibit to this Registration Statement on Form 8-A. A
copy of the Rights Agreement is available to Rights holders free of charge upon
request to the Corporate Secretary of the Company.

     This summary description of the Rights does not purport to be complete and
is qualified in its entirety by reference to the Rights Agreement, which is
hereby incorporated herein by reference.

CERTAIN ANTI-TAKEOVER EFFECTS

     The Rights approved by the Board of Directors of the Company are designed
to protect and maximize the value of the outstanding equity interests in the
Company in the event of an unsolicited attempt by an acquiror to take over the
Company, in a manner or on terms not approved by the Board of Directors.
Takeover attempts frequently include coercive tactics to deprive the Company's
Board of Directors and its stockholders of any real opportunity to determine the
destiny of the Company. The Rights have been declared by the Board of Directors
in order to deter such tactics, including a gradual accumulation of shares in
the open market of a 20% or greater position to be followed by a merger or a
partial or two-tier tender offer that does not treat all stockholders equally.
These tactics unfairly pressure stockholders, squeeze them out of their
investment without giving them any real choice and deprive them of the full
value of their shares.

     The Rights are not intended to prevent a takeover of the Company and will
not do so. The Rights may be redeemed by the Company at $0.01 per Right within
ten days after the accumulation of 20% or more of the Company's shares by a
single acquiror or group. Accordingly, the Rights should not interfere with any
merger or business combination approved by the Board of Directors.

     Issuance of the Rights does not in any way weaken the financial strength of
the Company or interfere with its business plans. The issuance of the Rights
themselves has no dilutive effect, will not affect reported earnings per share,
should not be taxable to the Company or to its stockholders, and will not change
the way in which the Company's shares are presently traded. The Company's Board
of Directors believes that the Rights represent a sound and reasonable means of
addressing the complex issues of corporate policy created by the current
takeover environment.

     However, the Rights may have the effect of rendering more difficult or
discouraging an acquisition of the Company deemed undesirable by the Board of
Directors. The Rights may cause substantial dilution to a person or group that
attempts to acquire the Company on terms or in a manner not approved by the
Company's Board of Directors, except pursuant to an offer conditioned upon the
negation, purchase or redemption of the Rights.

                                      -5-



Item 2.     Exhibits.

Exhibit 1.  Rights Agreement, dated as of October 7, 1998, by and
            between Bio-Technology General Corp. and American Stock
            Transfer & Trust Company as Rights Agent, which includes
            the form of Certificate of Designations setting forth
            the terms of the Series A Junior Participating
            Cumulative Preferred Stock, par value $0.01 per share,
            as Exhibit A, the form of Right Certificate as Exhibit B
            and the Summary of Rights to Purchase Preferred Shares
            as Exhibit C (incorporated by reference to Exhibit 4.1
            to the Company's Current Report on Form 8-K dated
            October 7, 1998).


                                      -6-




                                    SIGNATURE

     Pursuant to the requirements of Section 12 of the Securities Exchange Act
of 1934, the registrant has duly caused this registration statement to be signed
on its behalf by the undersigned, thereto duly authorized.



                                  BIO-TECHNOLOGY GENERAL CORP.



                                  By: /s/ SIM FASS
                                     ---------------------------
                                     Sim Fass
                                     Chairman of the Board, President and Chief
                                     Executive Officer


Dated:  October 8, 1998